New Blood Test Spots Over 50 Cancers Early

A revolutionary blood test, designed to detect over 50 types of cancer, has taken a significant step towards FDA approval. This multi-cancer early detection (MCED) screening, such as Grail's Galleri test, analyzes circulating cell-free DNA in the bloodstream, which may originate from tumor cells. If approved, it could enable earlier diagnosis for numerous cancers, including those lacking routine screening methods, potentially leading to more effective and less invasive treatments with improved patient outcomes. Researchers note that current screening protocols only identify about 14 percent of cancers. The majority of diagnoses occur due to patient-reported signs and symptoms, often resulting in later-stage detection. For example, certain cancers like pancreatic and ovarian cancers are frequently diagnosed at advanced stages, making treatment more complex and increasing mortality rates. However, concerns persist regarding the test's accuracy. Experts highlight the potential for false positives, which could cause undue stress, and false negatives, leading to a misleading sense of security. While studies have shown promising results, such as a fourfold increase in cancer detection when paired with standard screenings in one U.S. trial, the overall clinical value and impact on reducing cancer mortality are still under evaluation. The test's ability to predict the signal's origin is reported to be over 90 percent accurate. Currently priced at approximately $1,000, it is largely not covered by insurance. Approval is anticipated early next year, after which it is expected to be covered by most plans. Some medical professionals, while acknowledging the potential benefits, remain hesitant, suggesting that the marketing may currently outpace the scientific evidence.